Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
17.63
+0.30 (1.73%)
At close: Oct 22, 2024, 4:00 PM
17.72
+0.09 (0.51%)
After-hours: Oct 22, 2024, 5:31 PM EDT
Pacira BioSciences Employees
As of December 31, 2023, Pacira BioSciences had 712 total employees, including 711 full-time and 1 part-time employees. The number of employees decreased by 3 or -0.42% compared to the previous year.
Employees
712
Change (1Y)
-3
Growth (1Y)
-0.42%
Revenue / Employee
$969,537
Profits / Employee
$89,316
Market Cap
813.22M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
InnovAge Holding | 2,350 |
Embecta | 2,200 |
Cronos Group | 356 |
Perspective Therapeutics | 119 |
Arbutus Biopharma | 73 |
Annexon | 71 |
Dianthus Therapeutics | 53 |
Nuvation Bio | 51 |
PCRX News
- 1 day ago - Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - GlobeNewsWire
- 19 days ago - Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 - GlobeNewsWire
- 26 days ago - Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee - GlobeNewsWire
- 27 days ago - DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders - PRNewsWire
- 6 weeks ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 2 months ago - Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path - Benzinga
- 2 months ago - Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey - GlobeNewsWire
- 3 months ago - Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript - Seeking Alpha